A big pharma has entered the fray, teaming up with a biotech to create the first long-term stand-alone joint venture exploring the gene-editing technology Crispr-Cas9. German conglomerate Bayer AG and Switzerland-based CRISPR Therapeutics have created a joint venture that will explore the technology in three therapeutic areas.
The pair announced on Dec. 21 their London-based JV will develop therapies using new technology for "editing" defective genes to...